RECOVER aims to:

– Determine the effect of Kaftrio® on pulmonary function (FEV1 and LCI) in children and adults with CF over a period of 2 years.

– Determine the effect of Kaftrio® on spirometry-controlled CT scores in children and adults with CF over a 2-year period. 

– Investigate the effect of Kaftrio® on airway infection and inflammation in children and adults with CF.

– Assess the effect of Kaftrio® on nutrition, gastrointestinal symptoms, gut inflammation and pancreatic functions in children and adults with CF over a 2-year period. 

– Determine the effect of Kaftrio® on antibiotic treatment of pulmonary disease in children and adults with CF over a 2-year period. 

– Assess the impact of the introduction of Kaftrio® on adherence with overall medical treatments for CF. 

– Assess adolescents’ experience since starting Kaftrio® and young children’s understanding of CF and the treatments they receive.